Hvivo Plc (HVO) Ord 0.1p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Hvivo strikes £11.5m RSV contract with existing client
10 December 2024 08:01
(Sharecast News) - Contract research organisation Hvivo has struck a £11.5m Respiratory Syncytial Virus contract with an "existing top-tier global pharmaceutical client".
-
hVIVO upbeat on positive human challenge trial results with client
7 October 2024 10:21
(Sharecast News) - Specialist contract research organisation hVIVO announced positive results from a phase 2a human challenge trial (HCT) for Enanta Pharmaceuticals' RSV antiviral candidate, EDP-323, on...
-
hVIVO gets HSE clearance, launches new lab services
30 September 2024 10:19
(Sharecast News) - Specialist contract research organisation hVIVO launched the full suite of services provided by its hLAB division - a highly specialised virology and immunology laboratory supporting...
-
Hvivo delivers record revenues in H1, reiterates FY guidance
17 July 2024 08:46
(Sharecast News) - Contract research organisation Hvivo restated full-year guidance on Wednesday as the group revealed it had delivered record revenues in H1.
-
hVIVO secures biggest field study contract to date
2 July 2024 12:46
(Sharecast News) - Specialist contract research organisation hVIVO announced its engagement in a phase 2b field study for an influenza drug candidate on Tuesday.
-
Hvivo scores £2.5m contract for Omicron characterisation study
3 June 2024 10:35
(Sharecast News) - Contract research organisation Hvivo has secured a £2.5m contract with a mid-sized pharmaceutical company to initiate an Omicron characterisation study after the manufacture of its...
-
Hvivo unveils record results and bullish growth targets
9 April 2024 08:58
(Sharecast News) - Shares in AIM-listed Hvivo dipped on Tuesday despite the infectious and respiratory disease treatment firm reporting a record year across all financial and operational metrics, as well as...
-
hVIVO secures £6.3m contract with biotech client
2 January 2024 08:56
(Sharecast News) - Infectious and respiratory disease study group hVIVO has inked a £6.3m contract with an unnamed biotechnology client to test an antiviral candidate using its common cold virus human...
-
Sunday share tips: hVivo and On the Beach
24 December 2023 11:06
(Sharecast News) - Drug-testing specialist hVivo was one of the top tips for 2023 from The Daily Mail's Midas column, but the paper still reckons there's further to go despite the stock doubling in...
-
HVivo jumps on contract win, guidance upgrade
13 December 2023 08:20
(Sharecast News) - Shares in AIM-listed HVivo jumped on Wednesday morning after the clinical trials and laboratory services group won a new £17m contract and announced it was trading ahead of guidance.
-
hVIVO upbeat on positive results from recent FluCamp study
5 October 2023 15:15
(Sharecast News) - Contract research organisation hVIVO announced on Thursday that in a recent phase 2a influenza human challenge study it conducted, Pneumagen's antiviral candidate Neumifil...
-
hVIVO announces new Canary Wharf trial facility
29 August 2023 14:17
(Sharecast News) - Human challenge trial specialist hVIVO announced plans to open a new state-of-the-art facility at the rapidly-expanding life sciences hub in Canary Wharf, London on Tuesday.
Company announcements Announcements
-
COVID-19 study published in Nature Communications
12 December 2024 07:00
Hvivo
-
£11.5m RSV contract and notice of trading update
10 December 2024 07:00
Hvivo
-
Holding(s) in Company
19 November 2024 07:00
Hvivo
-
Holding(s) in Company
6 November 2024 07:00
Hvivo
-
Long Term Incentive Plan/ PDMR Notification
11 October 2024 07:00
Hvivo
-
Holding(s) in Company
24 September 2024 07:00
Hvivo
-
Holding(s) in Company
17 September 2024 07:00
Hvivo
-
Holding(s) in Company
13 September 2024 07:00
Hvivo
-
Interim results
10 September 2024 07:00
Hvivo
-
Holding(s) in Company
5 September 2024 07:00
Hvivo
-
Notice of results
20 August 2024 07:00
Hvivo
-
Holding(s) in Company
6 August 2024 15:07
Hvivo
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.